Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Contract Adding Thousands of Patients to Co.'s Telehealth Platform

Source: Streetwise Reports

September 6, 2023 ( Newswire) This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.

Telehealth company Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN) announced it has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024.

The iUGO platform helps manage diseases such as chronic obstructive pulmonary disease (COPD), congestive heart failure, diabetes, hypertension, and others. Patients get audible reminders to step on a scale, take their blood pressure, or prick their fingers for glucose monitoring. The information is automatically uploaded to the cloud.

"The iUGO Care platform supports patients with asthma, (COPD) and other breathing issues by providing remote monitoring with connected spirometers, inhalers, and nebulizers," said Reliq Chief Executive Officer Lisa Crossley. "According to the CDC (Centers for Disease Control and Prevention), over 20 million Americans have COPD, and it is the fourth-leading cause of death in the States. Remote monitoring of asthma and COPD patients allows health care providers to identify early changes in lung function that can be easily treated at home with antibiotics, steroid inhalers, or nebulizer treatments."

Drawing on data from fall detection devices, medication tracking, and vital signs, iUGO flags patients at home or in facilities who need additional monitoring.

These early interventions can prevent complications like inflammation, bronchitis, and pneumonia in COPD patients that can cause permanent lung damage and lead to lengthy intensive care unit stays.

Onboarding of the 10,000 patients, at US$65 per patient per month and greater than 70% gross margin, will begin this month, the company said.

The telehealth market was valued at US$128.12 billion in 2022 and is projected to grow to US$504.24 billion by 2030, a compound annual growth rate (CAGR) of 19.7%, according to Fortune Business Insights.

"The market is getting a significant boom with the rising start-up funding and launch of products, especially for virtual consultations," researchers wrote.

The COVID-19 pandemic brought the world to a standstill and put many burdens on healthcare workers.

"This has opened new market opportunities for digital health platforms," according to the report. "The demand for virtual consultations increased by many folds amid the crisis,

The Catalyst: 'Continuing Momentum'

The company is gathering "continuing momentum," wrote Maxim analyst Allen Klee, who rated the stock a Buy with a CA$1.75 per share target price. "We believe the company has hit an inflection point of accelerating revenue and EBITDA profitability. Tailwinds include a significant number of larger contracts that have been won."

Reliq had its first profitable quarter during the three months ending March 31 with a gain from operations of CA$731,017 YoY. It also has started scoring larger contracts for iUGO, including one with a U.S. health plan that operates in five states with more than 3,000 doctors and 1 million patients.

The company will not release its final results for fiscal year 2023, which ended June 30, until October. But Crossley recently told analysts and shareholders that according to estimates, revenues more than doubled from fiscal year 2022.

iUGO is a "compelling offer for practitioners," Klee wrote. "A typical practice can bring in more than US$1 million in Medicare and Medicaid payments implementing it."

"We project FY23 revenue of CA$17.1M, up 101% (YoY), in line with management's expectations for revenue to double in FY23 and implying F4Q23 revenue of CA$4.8M, up 110% (YoY)," Klee wrote. "For FY24, we project revenue of CA$34.2M, +99% (YoY), roughly in line with management's expectations for revenue doubling in F2024."

Klee's revenue predictions could prove conservative if the company is "successful in onboarding some of the larger contracts that have been announced," he wrote.

Little Effect from Idalia

Reliq, which has contracts in Florida, also announced that Hurricane Idalia did not significantly impact its clients there and "will not disrupt onboarding or billing for Reliq's clients in the state," Crossley said.

"Onboarding, adherence, and collections have continued to improve this quarter, and the company's profitability continues to increase," Crossley noted. "Sales for FY 2023 more than doubled year-over-year relative to FY 2022 and are expected to more than double again in FY 2024."

Recently, the company also announced it had signed contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands.

The contracts are expected to add more than 50,000 patients to iUGO by the end of 2024.

Ownership and Share Structure

About 8% of Reliq's shares are owned by insiders, including Crossley, with 1.6% or 3.22 million shares. About 0.3% of the company is owned by institutional investors, including FNB Wealth Management, with 0.01% or 0.03 million shares, according to Reuters.

Other top investors include Eugene Beukman, who owns 0.11% or 0.23 million shares, and Brian Storseth, who owns 0.07% or 0.14 million shares, Reuters said.

Crossley said 91.7% of the company is retail.

The company has 203 million shares outstanding, with about 200 million free-floating. It has a market cap of CA$91.3 million and trades in a 52-week range of CA$0.76 and CA$0.375.

More Info:

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy: - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on